Drug intelligence / Profile preview

FLT3 CAR NK

Development stage: Preclinical
Lead developer: CytoImmune Therapeutics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

FLT3 CAR NK is a chimeric antigen receptor (CAR) natural killer (NK) cell therapy developed by researchers at City of Hope. CytoImmune Therapeutics entered into a worldwide exclusive licensing agreement with City of Hope for the patent applications covering methods to generate large numbers of functional natural killer (NK) cells from umbilical cord blood and CAR compositions to target these NK cells to tumors. This cell therapy is designed to target Fms-like tyrosine kinase 3 (FLT3)-expressing tumor cells, with its primary indication being acute myeloid leukemia. CytoImmune Therapeutics is advancing this technology into clinical trials.

Targets

FLT3 (Fms related receptor tyrosine kinase 3)

Beyond the preview

Go deeper on FLT3 CAR NK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FLT3 CAR NK.

Explore the full profile